Ypsomed : Presentation of Half-Year Results 2023/24 (5.7 MiB)
November 15, 2023 at 05:10 am EST
Share
Ypsomed 2023/24 Half-Year Results
We deliver
Webcast, 15 November 2023
PUBLIC
Important information
The information contained in this document has not been verified by an independent source. It should be taken with caution and no assurance or guarantee is given (either explicit or implied) with regard to the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG nor advisors or affiliates of Ypsomed Holding AG shall be liable in any way for losses occurred in conjunction with the use of this document, its contents or any other connection with this document. This document is neither an offer (or part of an offer) for the sale, nor a solicitation for the purchase of shares, and neither the document nor parts thereof form the basis of any contract or otherwise obligation. This document contains future-oriented statements which include uncertainties and risks. Such statements are indicated by such words as "could", "planned", "expected", "believed" and similar expressions or their context. These statements are made based on current knowledge and current assumptions. Due to a variety of different factors, the actual future results, developments or events may deviate considerably from those mentioned here. There is no obligation whatsoever to update future- oriented statements.
2 | Ypsomed Holding AG | 2023/24 Half-Year Results
PUBLIC
Making selfcare simpler and easier
Improved therapy outcomes for chronic conditions
3 | Ypsomed Holding AG | 2023/24 Half-Year Results
PUBLIC
Solutions for healthcare's biggest challenge are our growth drivers
Selfcare
Improving quality of life, therapy adherence and supporting affordable healthcare systems
Biologics
Most new-generation drugs with complex active pharmaceutical ingredients must be injected
Biosimilars
Expanding global access to affordable medical care
Digitization
Enabling innovative, digital therapy management for optimal therapy outcomes and evidence-based care
4 | Ypsomed Holding AG | 2023/24 Half-Year Results
PUBLIC
Purpose and ambition
Growth drivers are lasting
Focused portfolio allows margin expansion
No "GLP-1 risk", in contrary
Continuous investment in innovation, capacity expansion and employee
Portfolio review ongoing
5 | Ypsomed Holding AG | 2023/24 Half-Year Results
PUBLIC
Turnover growth of 24 % from continued business
Ypsomed Group
Mail-order company DiaExpert GmbH in Germany was sold on 31 December 2022
6 | Ypsomed Holding AG | 2023/24 Half-Year Results
PUBLIC
Remarkable gross margin expansion
Higher utilisation of production capacities
Since 01 January 2023, absence of dilution by divested DiaExpert's trading business
7 | Ypsomed Holding AG | 2023/24 Half-Year Results
PUBLIC
Significant rise in EBIT from HY 2022/23 to HY 2023/24
8 | Ypsomed Holding AG | 2023/24 Half-Year Results
PUBLIC
Confirming outlook for the 2023/24 financial year
For the 2023/24 financial year, Ypsomed expects sales growth of the continued business of around 25 %
At EBIT level, Ypsomed confirms the outlook and expects an operating profit of at least CHF 90 million
9 | Ypsomed Holding AG | 2023/24 Half-Year Results
PUBLIC
10 Ypsomed Holding AG | 2023/24 Half-Year Results
Attachments
Original Link
Original Document
Permalink
Disclaimer
Ypsomed Holding AG published this content on 15 November 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 November 2023 10:08:07 UTC.
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.